Kezar Life Sciences, Inc.
NASDAQ:KZR
Overview | Financials
Company Name | Kezar Life Sciences, Inc. |
Symbol | KZR |
Currency | USD |
Price | 6.84 |
Market Cap | 49,906,145 |
Dividend Yield | 0% |
52-week-range | 5.2 - 11.4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Franklin Fowler |
Website | https://www.kezarlifesciences.com |
An error occurred while fetching data.
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD